GRI Bio Presents Preclinical Data From Pipeline Of NKT Cell Modulators In Development For Systemic Lupus Erythematosus
Portfolio Pulse from Benzinga Newsdesk
GRI Bio presented preclinical data on its NKT cell modulators for Systemic Lupus Erythematosus at the 14th International Congress on Autoimmunity. The data is promising and comparable to OFEV® (nintedanib), a leading tyrosine kinase inhibitor. GRI Bio plans to file an IND for GRI-0803 in Q3 2024, with topline data expected in Q4 2024.
May 21, 2024 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GRI Bio presented promising preclinical data on its NKT cell modulators for Systemic Lupus Erythematosus, comparable to OFEV®. The company plans to file an IND for GRI-0803 in Q3 2024, with topline data expected in Q4 2024.
The promising preclinical data and the timeline for IND filing and topline data release are positive indicators for GRI Bio's future prospects. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100